Korea Electric Power Down Nearly 8%, on Pace for Largest Percent Decrease Since January 2023 — Data Talk
Korea Electric Power Corporation Sponsored ADR (KEP) is currently at $7.57, down $0.64 or 7.8%
--Would be lowest close since Aug. 20, 2024, when it closed at $7.51
--On pace for largest percent decrease since Jan. 3, 2023, when it fell 10.19%
--Currently down five consecutive days; down 10.41% over this period
--Longest losing streak since Oct. 24, 2023, when it fell for 10 straight trading days
--Worst five day stretch since the five days ending May 14, 2024, when it fell 10.59%
--Down 7.23% month-to-date; on pace for worst month since April 2024, when it fell 8.16%
--Up 4.41% year-to-date
--Down 73.26% from its all-time closing high of $28.31 on Aug. 10, 2016
--Up 14.52% from 52 weeks ago (Sept. 25, 2023), when it closed at $6.61
--Down 20.32% from its 52-week closing high of $9.50 on March 14, 2024
--Up 27.01% from its 52-week closing low of $5.96 on Oct. 26, 2023
--Traded as low as $7.55; lowest intraday level since Aug. 20, 2024, when it hit $7.48
--Down 8.04% at today's intraday low; largest intraday percent decrease since Jan. 3, 2023, when it fell as much as 12.04%
All data as of 12:59:29 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 23, 2024 13:18 ET (17:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk